MM-3001

MM-3001 is a second-generation short lipidated peptide (SLiP) designed for the treatment of neuropathic pain, specifically diabetic peripheral neuropathy. Developed as part of the MM-3000 series, it targets membrane-delimited protein-protein interactions between scaffold proteins and the voltage-gated sodium channel Nav1.8. By disrupting these complexes, MM-3001 selectively reduces Nav1.8 currents in hyperexcitable dorsal root ganglion (DRG) neurons, which are primary sites for injury-induced plasticity in peripheral neuropathies. This mechanism leads to a reduction in action potential firing and an increase in rheobase. Preclinical evaluations in rodents and minipigs have demonstrated that systemic administration of MM-3001 produces significant, dose-dependent reductions in neuropathic pain-like behaviors, offering a potential non-opioid therapeutic alternative for patients who respond inadequately to existing treatments.